New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
09:11 EDTIMS, SQBG, GLNG, BMY, BKS, CVRR, OMI, AERI, GIS, PXD, MDCI, NSPH, MONOn The Fly: Pre-market Movers
HIGHER: Barnes & Noble (BKS), up 7.7% after board authorizes management to separate Retail, Nook Media units... Monsanto (MON), up 5% after reporting better than expected Q3 results, raising its full year EPS outlook to the upper end of its previous guidance range and announcing a new $10B share repurchase authorization... IMS Health (IMS), up 7.7% after acquiring certain Cegedim businesses for $520M... Nanosphere (NSPH), up 16.2% after receiving 510(k) clearance for bacterial portion of Verigene EP test... Aerie Pharmaceuticals (AERI), up 37% after its trial of Roclatan achieved its primary efficacy endpoint... Medical Action (MDCI), up 94% after Owens & Minor (OMI) acquires the company for $13.80 per share in cash... Sequential Brands (SQBG), up 15% after acquiring Galaxy Brand for $100M cash, 13.75M shares... Pioneer Natural (PXD), up 2.3% after media reports that the company got U.S. permission to ship a type of light oil known as condensate... Bristol-Myers Squibb (BMY), up 2% after a Phase 3 study of nivolumab was halted early due to superior data. LOWER: General Mills (GIS), down 3.7% after Q4 earnings fall below analyst's consensus... Lindsay Corp. (LNN), down 5% after earnings miss, saying Iraq contract now more difficult to complete... Golar LNG (GLNG), down 2% after 11M share offering priced at $54 per share... CVR Refining (CVRR), down 7% after 6M share secondary offering of common units price at $26.07.
News For BKS;MON;GIS;BMY;NSPH;AERI;GLNG;MDCI;OMI;SQBG;PXD;CVRR;IMS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
August 26, 2015
10:38 EDTMONMonsanto confirms confidence in more than doubling FY14 ongoing EPS by 2019
Subscribe for More Information
10:37 EDTMONMonsanto says no longer pursuing current proposal for Syngenta combination
Subscribe for More Information
10:36 EDTMONMonsanto says no longer pursuing current proposal for Syngenta combination
Subscribe for More Information
10:22 EDTMONSyngenta trading halted, news pending
Subscribe for More Information
10:20 EDTMONMonsanto trading halted, pending news
August 25, 2015
13:10 EDTMONSyngenta investor: CHF470 per share 'good price,' Reuters reports
Subscribe for More Information
09:47 EDTMONSeveral Monsanto shareholders opposed to Syngenta pursuit, CNBC reports
Subscribe for More Information
August 24, 2015
12:17 EDTMONMonsanto to raise Syngenta bid to about CHF470 per share, Bloomberg says
Subscribe for More Information
11:44 EDTMONMonsanto to raise Syngenta bid to about CHF 470 per share, Bloomberg says
This would equate to about $47B and be up from CHF 449 per share previously, Bloomberg noted.
09:45 EDTBMYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Bank of America (BAC) upgraded to Outperform from Market Perform at Keefe Bruyette... Bristol-Myers (BMY) upgraded to Neutral from Underweight at Piper Jaffray... Chevron (CVX) upgraded to Neutral from Underperform at BofA/Merrill... Abercrombie & Fitch (ANF) upgraded to Overweight from Neutral... Nike (NKE) upgraded to Outperform from Market Perform at Telsey Advisory... DreamWorks (DWA) upgraded to Buy from Neutral at B. Riley... Caesarstone (CSTE) upgraded to Overweight from Equal Weight at Barclays... TransAlta (TAC) upgraded to Outperform from Market Perform at BMO Capital... Sarepta (SRPT) upgraded to Overweight from Neutral at Piper Jaffray... AutoZone (AZO) upgraded to Buy from Neutral at BofA/Merrill... Royal Dutch Shell (RDS.A) upgraded to Buy from Hold at Jefferies... Allscripts (MDRX) upgraded to Buy from Hold at Argus... China Unicom (CHU) upgraded to Buy from Hold at Jefferies... Ross Stores (ROST) upgraded to Buy from Neutral at Buckingham.
08:16 EDTBMYBristol-Myers, Pfizer to present new data on Eliquis at ESC Congress 2015
Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) announced that 22 abstracts will be presented at the ESC Congress 2015, to be held August 29 to September 2 in London, United Kingdom. The new data reinforce the Alliance's commitment to the ongoing evaluation of Eliquis in both the nonvalvular atrial fibrillation and venous thromboembolism patient populations. In addition, data from the AEGEAN study evaluating adherence among NVAF patients further extends the Alliance's commitment to patient care.
07:08 EDTBMYBristol-Myers upgraded to Neutral from Underweight at Piper Jaffray
Subscribe for More Information
August 23, 2015
12:35 EDTBMYBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 20, 2015
06:01 EDTBMYBristol-Myers announces Canadian approval of Daklinza
Subscribe for More Information
August 19, 2015
05:46 EDTBMYStocks with implied volatility movement; ESRX BMY
Subscribe for More Information
August 18, 2015
08:16 EDTAERIAerie Pharmaceuticals trial results likely to be positive, says RBC Capital
Subscribe for More Information
07:22 EDTBMYBristol-Myers combo data could push shares above $70, says JPMorgan
JPMorgan analyst Chris Schott says the risk/reward for shares of Bristol-Myers Squibb looks "very attractive" ahead of the World Conference on Lung Cancer, which begins September 6. Data at the conference supportive of an Opdivo/Yervoy combo would represent a clear catalyst for the shares, Schott tells investors in a research note. Bristol is "already extremely well-positioned" in the advanced non-small cell lung cancer market, and data suggesting that the company has addressed toxicity concerns with the combo could push the stock above $70, Schott argues. Bristol closed yesterday up 39c to $63.47. The analyst sees limited downside to stock even with disappointing results at the World Conference on Lung Cancer. He reiterates an Overweight rating on Bristol with a $75 price target.
07:03 EDTGLNGDynagas, GasLog, Golar LNG to establish, operate LNG Carrier Pool
Subscribe for More Information
07:02 EDTGLNGDynagas, GasLog, Golar enter LNG Carrier Pool agreement
Dynagas (DLNG), GasLog (GLOG), and Golar LNG (GLNG), jointly announce that they have entered into an LNG carrier pooling agreement to market their vessels, which are currently operating in the LNG shipping spot market. Tony Lauritzen has agreed to take overall responsibility for the running of The Cool Pool and Morten Nielsen has been appointed as Pool Manager, with the mandate to schedule employment for each pool vessel. The Cool Pool will focus exclusively on charters of 12 months duration or less. The scheduling of employment opportunities in excess of 12 months will remain the mandate of the respective vessel owner. If a pool vessel is scheduled by an owner for a charter that exceeds 12 months in duration such vessel will cease to form part of the LNG Carrier Pool's fleet. It is anticipated that The Cool Pool will commence operation in September 2015.
August 17, 2015
08:43 EDTBMYBristol-Myers sells Ixempra to R-PHARM, terms not disclosed
R-PHARM announces the acquisition of Ixempra from Bristol-Myers Squibb. Ixempra received marketing approval from the FDA in 2007 and in 18 other markets globally. Ixempra is indicated as monotherapy or in combination with capecitabine for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine. With the acquisition, R-PHARM has launched its U.S. commercial operations, and it is now responsible for all activities surrounding Ixempra's manufacture, distribution, sales, and reimbursement. Financial terms were not disclosed.
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use